

RESEARCH ARTICLE

Open Access

Radiosensitization of mammary carcinoma cells by telomere homolog oligonucleotide pretreatment

Desheng Weng^{1†}, Monique C Cunin^{1†}, Baizheng Song¹, Brendan D Price², Mark S Eller³, Barbara A Gilcrest³, Stuart K Calderwood⁴, Jianlin Gong^{1*}

Abstract

Introduction: Ionizing radiation (IR) is a widely used approach to cancer therapy, ranking second only to surgery in rate of utilization. Responses of cancer patients to radiotherapy depend in part on the intrinsic radiosensitivity of the tumor cells. Thus, promoting tumor cell sensitivity to IR could significantly enhance the treatment outcome and quality of life for patients.

Methods: Mammary tumor cells were treated by a 16-base phosphodiester-linked oligonucleotide homologous to the telomere G-rich sequence TTAGGG (T-oligo: GGTTAGGTGTAGGTTT) or a control-oligo (the partial complement, TAACCTAACCTAAC) followed by IR. The inhibition of tumor cell growth *in vitro* was assessed by cell counting and clonogenic cell survival assay. The tumorigenesis of tumor cells after various treatments was measured by tumor growth in mice. The mechanism underlying the radiosensitization by T-oligo was explored by immunofluorescent determination of phosphorylated histone H2AX (γ H2AX) foci, β -galactosidase staining, comet and Terminal deoxynucleotidyl transferase dUTP Nick End Labeling (TUNEL) assays. The efficacy of the combined treatment was assessed in a spontaneous murine mammary tumor model.

Results: Pretreatment of tumor cells with T-oligo for 24 hours *in vitro* enhanced both senescence and apoptosis of irradiated tumor cells and reduced clonogenic potential. Radiosensitization by T-oligo was associated with increased formation and/or delayed resolution of γ H2AX DNA damage foci and fragmented DNA. T-oligo also caused radiosensitization in two *in vivo* mammary tumor models. Indeed, combined T-oligo and IR-treatment *in vivo* led to a substantial reduction in tumor growth. Of further significance, treatment with T-oligo and IR led to synergistic inhibition of the growth of spontaneous mammary carcinomas. Despite these profound antitumor properties, T-oligo and IR caused no detectable side effects under our experimental conditions.

Conclusions: Pretreatment with T-oligo sensitizes mammary tumor cells to radiation in both *in vitro* and *in vivo* settings with minimal or no normal tissue side effects.

Introduction

Breast cancer is the most common malignancy among women in the United States. It is estimated that each year 192,370 new cases will occur and 40,170 women will die from the disease (American Cancer Society Facts and Figures, 2009). Current therapies, usually in combination with surgical excision, have reduced the

mortality from this disease but remain inadequate for many and may produce serious side effects. Ionizing radiation (IR) is one of the most widely used therapies but the therapeutic effect is dependent on the sensitivity of the breast cancer cells to radiation. Thus, promoting tumor cell sensitivity to IR could significantly enhance the treatment outcome and quality of life for patients. Recent studies show that telomeres are implicated in the maintenance of genomic stability and repairing of damaged DNA. Therefore, telomere-based therapy may

* Correspondence: jgong@bu.edu

† Contributed equally

¹Department of Medicine, Boston University School of Medicine, 72 E Concord St, Boston, MA 02118, USA

Full list of author information is available at the end of the article

provide a promising approach to enhancing the effect of radiotherapy and/or reducing its side effects.

Telomeres consist of guanine-rich tandem repeats that prevent chromosome ends from being recognized as DNA double-strand breaks. McClintock's historical observation that loss of telomeric sequences in maize chromosomes renders DNA ends recombinogenic highlighted the importance of telomeres and their associated complexes in chromosomal integrity [1]. More recent work has established that disruption of the T-loop by experimental DNA damage, telomere shortening or expression of a dominant-negative mutant of loop-binding factor leads to cellular apoptosis or senescence [2,3].

A novel approach to treating cancer involves harnessing innate telomere-based DNA damage responses through use of telomere homolog oligonucleotides, termed T-oligos. Like experimental disruption of the normal telomere loop structure [4], T-oligo treatment of cancer cells *in vitro* or *in vivo* leads to apoptosis and/or senescence, depending on cell type [5-9]. However, unlike treatments that disrupt the telomere loop, T-oligos do not cause digestion of the 3' telomere overhang (repeats of TTAGGG sequences) or otherwise alter endogenous chromosomes [10]. Systemic administration of T-oligos greatly reduces tumor burden in xenograft mouse models of human melanoma and breast carcinoma [6,8]. In addition, when used in combination with conventional chemotherapy to treat human lymphoma cells *in vitro* or to treat a murine B cell lymphoma in a mouse model, T-oligos reduced the dose of these toxic agents required to achieve cell killing [11]. The detailed mechanism of tumor inhibition by T-oligo is not fully elucidated. However, it is believed that the guanine (G)-rich T-oligos enhance G quadruplex formation in single-stranded telomeric DNA (repeats of TTAGGG), stall DNA replication forks and promote DNA damage responses that lead to cellular senescence and apoptosis [12]. Selective killing of malignant cells, with sparing of normal cells, likely results from the well-recognized greater sensitivity of malignant cells to replication stress, especially those with abnormalities in the breast cancer-associated gene (*BRCA*) pathway [13,14], with fatal collapse of stalled replication forks at sites of G-quadruplex formation.

In the present study, we tested the hypothesis that T-oligo treatment sensitizes tumor cells to ionizing radiation. T-oligos have been shown to inhibit growth and induce apoptosis, autophagy and/or senescence in human pancreatic, ovarian, breast cancer, melanoma, fibrosarcoma, and glioblastoma [5-9]. Our data indicate that pretreatment of mammary tumor cells with T-oligo but not a control oligo sensitizes the tumor cells to radiation *in vitro* and in an *in vivo* tumor model.

Materials and methods

Mice

Female C57BL/6 mice, six to eight weeks old, were purchased from Taconic Farms (Germantown, NY, USA). MMT mice were generated by breeding MUC1 transgenic (MUC1.Tg) mice with polyomavirus middle T oncogene (PyMT)-expressing MT mice that develop spontaneous mammary carcinomas [15,16]. Animals were maintained in microisolator cages under specific pathogen-free conditions. The study of mice was approved by the Institutional Animal Care and Use Committee of Boston University Medical Center.

Oligonucleotides

A 16-base phosphodiester-linked oligonucleotide (T-oligo: GGTTAGGTGTAGGTTT) with 56% homology to the human telomere G-rich sequence [7], and a control-oligo (the partial complement, TAACCCTAACCC-TAAC) were synthesized by the Midland Certified Reagent Company (Midland, TX, USA) and resuspended in H₂O to give a 2 mM stock solution. For the *in vitro* studies, the stock solution was diluted into culture medium, and added to cells at a final concentration of 40 μM. In all experiments, cells were given medium containing oligonucleotide once and not refed. For the *in vivo* studies, 2 mM of T-oligo and control-oligo were diluted in sterile PBS to make a 1.2 mM concentration and 50 μL of this solution was injected into each mouse.

Earlier studies of T-oligos employed 100% homologs [5-11], establishing the efficacy for telomere homologs in comparison to inactive complementary and unrelated control sequences. However, further work revealed that G-rich oligos with substantial but less than 100% homology to telomeres were also effective in activation of the DNA damage signaling pathway leading to apoptosis of malignant cells and that some were even more effective than the same length 100% homologs [7]. One of these 16-base T-oligos was selected for the present studies.

Cell yield and counting

Primary mammary tumor cells from MMT mice were harvested and cultured in Dulbecco's Modified Eagle's Medium (DMEM) with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. A triplicate set of cultured cells was pre-treated with T-oligo or control-oligo at a final concentration of 0, 10, 20, 30 or 40 μM in DMEM for 24 hours, and then irradiated with 0, 3, 6, 9, or 12Gy (Cesium¹³⁷ source at a dose rate of 1.06 Gy/min). The cells were trypsinized and collected at 0, 24, 48, 72 and 96 hours after irradiation for cell count using a cell counter (Coulter Corp., Miami, FL, USA).

Clonogenic survival assay

Mammary tumor cells were trypsinized to a single-cell suspension and seeded into 10 cm tissue culture dishes (1×10^5 cells/dish). After the cells were treated with 40 μ M T-oligo or control-oligo for 24 hours, they were irradiated at different dose levels (0 to 8 Gy) and placed thereafter in an incubator until cells in the control groups formed multiple large clones. The colonies were stained with 0.5% crystal violet and counted. The plating efficiency (PE) and the surviving fraction (SF) were calculated by using the formula $PE = (\text{number of colonies formed}/\text{number of cells seeded}) \times 100\%$ and $SF = (\text{number of colonies formed after treatment}/\text{number of cells seeded} \times PE) \times 100\%$. The standard radiation survival curve was constructed and the mean lethal dose (D_0), which represents the dose required to reduce the fraction of surviving cells to 37% (1/e) of its previous value, was calculated by fitting the data with the multitarget-single hit model and linear-quadratic model [17].

Immunofluorescent γ H2AX staining

Tumor cells plated into eight-well chambers were pretreated with T-oligo or control-oligo for 24 hours and then irradiated. After radiation, cells were fixed in 4% paraformaldehyde, and then treated with a 0.2% NP40/PBS solution for 15 minutes at room temperature. Cells were washed with PBS and incubated for two hours with anti- γ H2AX (1:300 dilution, Upstate Biotechnology, Lake Placid, NY, USA), followed by incubation with FITC-conjugated anti-mouse IgG (1:100 dilution) for one hour. Slides were immersed in 0.05 mg/ml DAPI for five minutes and then mounted with cover slips using ProLong[®] Antifade Kit (Molecular Probes Inc., Eugene, OR, USA). Slides were viewed with a Nikon Eclipse E400 fluorescence microscope (Nikon Inc., Tokyo, Japan) and the images were captured by a digital camera and analyzed using SPOT advanced software (Version 4.6, Diagnostic Instrument Inc., Sterling Heights, MI, USA). The number of γ H2AX-foci per cell was counted and determined in at least 70 cells for each group [18].

Single cell gel electrophoresis assay

To compare the degree of DNA fragmentation, mammary tumor cells were pretreated with 40 μ M T-oligo or control-oligo for 24 hours, and then subjected to irradiation. Three hours after radiation, cells were trypsinized to single-cell suspension and adjusted to the concentration of 1×10^5 cells/ml. Cell suspensions (10 μ l) and 1% low melting-point (LMP) agarose (100 μ l) were gently mixed at 37°C and added onto each CometSlide[™] (Trevigen Inc., Gaithersburg, MD, USA). The slides were gelled at 4°C in the dark for 30 minutes, and then immersed in prechilled lysis solution (2.5 M NaCl,

100 mM EDTA, 10 mM Tris) for 60 minutes. Then the slides were immersed in freshly prepared alkaline buffer (300 mM NaOH, 1 mM EDTA, pH > 13.0) for 60 minutes to allow the DNA to unwind prior to electrophoresis at 1 Volt/cm for 30 minutes at 4°C. Air-dried slides were stained for five minutes with 10 μ l DAPI (0.05 mg/ml), and then rinsed in cold water and covered with a cover slip. The nuclei were analyzed by use of a fluorescence microscope. Hydroxyl radical-induced DNA damage by H₂O₂ was used as a positive control. TriTek CometScore[™] (Version 1.5.2.6, Sumerduck, VA, USA) software was used to measure the percentage of DNA in tail. At least 45 cells on each slide were measured.

β -galactosidase staining

Mammary tumor cells were cultured in either medium alone or medium containing T-oligo or control T-oligo at a concentration of 40 μ M for 24 hours, and then irradiated with 3 Gy. Twenty-four hours after radiation, the cells were washed in PBS and fixed with formaldehyde/glutaraldehyde solution (5.6% formaldehyde, 0.4% glutaraldehyde in PBS) for 10 minutes at room temperature and stained with an X-gal mixture (40 mM Citrate/Na₂HPO₄, 5 mM K₄Fe(CN)₆, 5 mM K₃Fe(CN)₆, 150 mM NaCl, 2 mM MgCl₂, 1 mg/ml X-Gal) [19] for 24 hours at 37°C. To quantify the β -gal positive cells, three to five high-power fields per mouse were selected and β -gal positive cells were counted as described [19,20] by two investigators.

TUNEL assay

To determine apoptosis in tumor cells treated with T-oligo and radiation, TUNEL staining was performed using ApopTag Plus peroxidase kit (Chemicon, Temecula, CA, USA) in a method previously described with some modification [21,22]. To quantify the apoptotic cells, three to five high-power fields per mouse were selected and apoptotic cells were counted by two investigators.

Tumorigenesis of cancer cells treated with T-oligo and radiation

To assess the growth potential of T-oligo and IR-treated tumor cells in mice, mammary tumor cells were supplemented in culture with T-oligo for 24 hours, and then irradiated with 3 Gy. The tumor cells cultured in medium alone or containing control-oligo were used as control groups. After radiation, the cells were washed and prepared for injection. Untreated cells were resuspended in PBS, while the control-oligo and T-oligo-treated cells were resuspended in 1.2 mM control-oligo or T-oligo in PBS. T-oligo or control-oligo-treated and medium only (diluent)-treated tumor cells (1×10^6 cells in 0.1 ml volume/mouse) were injected respectively in the right or

left flanks of syngeneic wild-type mice. Untreated tumor cells with or without IR were also injected as controls. The mice were followed for up to 30 days after the tumor inoculation and tumor growth was measured with calipers every two days. The tumor incidence was also recorded.

In vivo treatment

MMT mice at approximately 73 days of age were injected intraductally in the right chest mammary gland with 50 μ L of a T-oligo solution (210 μ g = 60 nmol in 50 μ L of PBS). The left chest mammary gland in the same mouse was injected with the same dosage of control-oligo. After seven to eight daily injections, the mice were sedated with intraperitoneal administration of ketamine (75 mg/kg) and xylazine (5 mg/kg) and placed in a special Irradiation Pie cage. The mammary glands (chest area) were irradiated with 3 Gy IR with the rest of the body covered by lead foil. The mice were sacrificed 10 days after the radiation. The treated mammary glands were then removed, whole-mounted, formalin-fixed, stained in carmine alum, and photographed with a digital camera. To quantify the tumor burden, digital images of all whole mounted mammary glands were analyzed using SPOT advanced software.

Statistical analysis

Statistical significance was determined using Student's *t*-tests or χ^2 -test. One way-ANOVA was used for analysis of data with more than two subgroups.

Results

Sensitization of tumor cells to radiation by T-oligo


To determine if T-oligo can enhance the inhibition of mammary tumor cell growth due to radiation, tumor cells from MMT mice were cultured with T-oligo at concentrations ranging from 0 to 40 μ M for 24 hours and then irradiated. Tumor cells cultured in DMEM medium alone or DMEM containing the same concentration of a control oligo were used as controls. The cells were collected and counted at 0, 24, 48, 72 and 96 hours after exposure to 3 Gy IR. T-oligo alone inhibited growth of tumor cells in a dose dependent manner, with the most marked inhibition at 40 μ M T-oligo (data not shown). However, inhibition was significantly enhanced after IR and significant inhibitory effects were observed in tumor cells treated with 30 to 40 μ M T-oligo and 3 Gy IR (Figure 1a). This group of tumor cells declined in numbers while the control-oligo-treated tumor cells, though exposed to the same dose of 3 Gy, continued to replicate (Figure 1a). These results suggest enhanced inhibition of mammary tumor cells treated with T-oligo and 3 Gy radiation. The inhibition of growth after 40 μ M T-oligo and 3 Gy IR was more pronounced than in

cells treated with control-oligo or diluent alone ($P = 0.019$) and 6, 9 or 12 Gy (Figure 1b).

The clonogenic cell survival assay is the gold standard to measure the radiosensitivity of cells. To determine if T-oligo can sensitize mammary tumor cells to radiation, tumor cells pretreated for 24 hours with T-oligo, control-oligo or medium alone were irradiated with indicated doses of radiation and then the surviving fraction of cells (those capable of colony formation) was determined. As shown in Figure 1c, the survival curve of tumor cells treated with T-oligo and IR shifted to the left considerably compared with those treated with control-oligo or medium and 3 Gy, suggesting significant radiosensitization of tumor cells by T-oligo (Figure 1c). The mean lethal dose (D_0) for tumor cells treated with radiation plus T-oligo, control-oligo or medium alone was 1.46, 2.98 and 3.36 Gy, respectively (Figure 1c). The survival fraction at 2 Gy ($SF_2 = 0.31$) for tumor cells treated with T-oligo and radiation are comparable to those of cell lines considered to be radiosensitive [23]. Thus pretreatment with T-oligo increases the sensitivity of tumor cells to radiation and the combined treatment with T-oligo and radiation can lead to cell growth arrest and/or death as demonstrated by the clonogenic assay.

Mechanism of T-oligo-induced hypersensitivity to radiation

To investigate potential mechanisms behind radiosensitization of tumor cells by T-oligo, we next examined the levels of nuclear-foci containing phosphorylated H2AX (H2AX), a modification that occurs at sites of DNA breaks [24]. Figure 2a shows representative immunofluorescent images of γ H2AX foci in treated mammary tumor cells. Increased numbers of γ H2AX foci per cell were observed in tumor cells treated with T-oligo and 3 Gy IR at every time point after radiation compared with those in tumor cells treated with control-oligo or medium alone and 3 Gy (Figure 2a, b). The difference in γ H2AX-focus number between tumor cells treated with T-oligo and IR and control groups at 1, 3, 6 and 24 hours is statistically significant (Figure 2b). These results suggest that T-oligo enhances radiation-induced DNA damage signal and/or delays DNA repair, although T-oligo alone is known to transiently induce γ H2AX foci at telomeres in the apparent absence of double strand DNA breaks or other damage [25]. We next compared DNA fragmentation in tumor cells treated with T-oligo and 3Gy IR using the comet assay [26]. Very modest DNA fragmentation indicated by percentage of DNA in tails, was observed in tumor cells treated with T-oligo or 3 Gy IR alone, while cells treated with control-oligo or medium alone showed no fragmentation (Figure 2c, d). However, a significantly greater amount of fragmented DNA was detected three hours after 3 Gy IR



treatment in T-oligo-pretreated cells (Figure 2c, d). Thus, combined treatment with T-oligo and radiation results in enhanced response to DNA damage and/or impaired DNA repair, leading to growth arrest and cell death.


Increased induction of senescence and apoptosis in tumor cells pretreated with T-oligo

As the above studies show that cells pretreated with T-oligo are more sensitive to IR, we next determined whether the treated cells undergo senescence or apoptosis. Tumor cells isolated from MMT mice were pretreated with T-oligo or control-oligo followed by radiation and then examined 24 hours later for the induction of senescence or apoptosis using senescence-associated β -galactosidase (S.A. β -gal) and TUNEL staining, respectively. Increased numbers of large (flattened) cells positive for S.A. β -gal, two markers of senescent cells, were observed after T-oligo treatment compared with control-oligo treatment or medium alone. However, β -gal-positive cells increased significantly in tumor cells treated with T-oligo and 3 Gy compared with control-oligo or no treatment and 3 Gy ($58.3 \pm 6.3\%$ vs $34.2 \pm 7.5\%$ or $26.1 \pm 6.2\%$, Figure 3a, b). A more profound effect of combined T-oligo and IR was detected using the TUNEL assay. The apoptotic

rate increased significantly to $20.8 \pm 8.5\%$ ($P = 0.036$), two to four times the control rates, in tumor cells treated with T-oligo and 3 Gy (Figure 3c, d). These results indicate that senescence and apoptosis may be important pathways to inhibit proliferation of murine mammary tumor cells treated with T-oligo and IR. Both responses may also contribute to the observed decrease in clonogenic ability. Given that rates of senescence and apoptosis have been previously observed to increase steadily in T-oligo-treated malignant cells over two to four days, depending on cell type [5-8], these determinations made only 24 hours after irradiation, preceded by an overnight T-oligo incubation, may underestimate the eventual impact of the treatment.


Decreased tumorigenesis in mammary tumor cells treated with T-oligo and irradiation

To determine whether tumor cells can still form tumors *in vivo* after treatment with T-oligo and radiation, mammary tumor cells were preincubated with T-oligo or control-oligo for 24 hours followed by exposure to 0 Gy (mock) or 3 Gy. The other control groups were tumor cells supplemented with medium (diluent) alone or exposed to 3 Gy of radiation alone. The tumor cells (1×10^6) were then injected subcutaneously into the flanks of syngeneic wild-type mice. As



shown in Figure 4a, all mice inoculated with tumor cells pretreated with T-oligo alone developed tumors, but tumor size was reduced when compared with untreated and control-oligo-treated tumor cells on Day 30 (Figure 4a, $P = 0.02$). However, the tumor forming ability of mammary tumor cells treated with combined T-oligo and 3 Gy irradiation was almost eradicated. Only one out of four mice developed a tumor and this small tumor did not appear until after Day 25 (Figure 4b). The difference in volume for tumor arising from cell populations treated with T-oligo vs control-oligo or medium alone, followed by 3 Gy, was highly statistically significant ($P = 0.001$, Figure 4b). Next, to determine if T-oligo and radiation induce apoptosis in tumor cells injected into mice, sections of tumors from all groups were stained for apoptosis using the TUNEL assay. In tumors arising from cells pretreated once with T-oligo alone we observed far more apoptosis even after 30 days compared with control-oligo or


medium alone (Figure 4c). Few or no TUNEL-positive cells were observed in tumors arising from control-oligo or medium treated cells, and 3 Gy irradiation did not increase the apoptosis to a statistically significant degree (Figure 4c, d). In tumors arising from cells treated with combined T-oligo and radiation, the numbers of apoptotic cells increased significantly ($P = 0.043$) even after 30 days. At this time, an approximately three- to six-fold increase in apoptosis was observed in tumor cells treated with T-oligo vs control-oligo or medium alone prior to subcutaneous injection (Figure 4d). The one small tumor found in one mouse inoculated with tumor cells treated with T-oligo followed by 3 Gy IR contained many apoptotic cells (Figure 4c, bottom right panel). These experiments provide further evidence that pretreatment with T-oligo can enhance the apoptotic killing of tumor cells by radiation, even by radiation doses that alone have only a modest effect.



Effect of combined T-oligo and radiotherapy on spontaneous mammary carcinomas *in vivo*

When evaluating the efficacy of a therapy for breast cancer, it is desirable to use a tumor model that resembles breast cancer in humans as closely as possible. We [16,27] and others [15,28] have demonstrated that PyMT-induced mammary tumors share many features in common with human breast cancer. Therefore, MMT mice were used to evaluate the combined effect of T-oligo and radiotherapy in the *in vivo* setting. Our previous studies showed that mammary tumors in MMT mice at Days 70 to 80 are in the early invasive stage [16]. MMT mice ($n = 9$) aged 70 to 72 days received intraductal injections of T-oligo at a dose of 210 μ g in 50 μ L PBS every other day in a right chest mammary gland. A left chest mammary gland was injected with the same dose of control-oligo as a same animal control. After seven to eight injections, the mice were irradiated with a single dose of 3 Gy focused on the chest area. The control groups consisted of three littermates each that received no treatment, treated with T-oligo and control-oligo without radiation or treated with 3 Gy IR alone. Ten days after irradiation, the mice were sacrificed and the treated and control mammary glands harvested, processed for


whole mount, and digitized. The tumor in the digital image was traced and analyzed by SPOT advanced software. As shown in Figure 5a, b, mammary tumors in the mice without treatment or treated with 3 Gy alone reached the size of 58 ± 6.11 mm² and 48 ± 14.18 mm², respectively, statistically comparable. Treatment with T-oligo or control-oligo without irradiation resulted in tumor sizes of 20.3 ± 8.96 mm² and 48.6 ± 30.1 mm², respectively. However, the average tumor size in the right mammary gland treated with T-oligo and 3Gy IR was reduced to 8.67 ± 3.61 mm², compared with the average tumor size of 27.67 ± 8.69 mm² in the left mammary gland treated with control-oligo and 3 Gy IR. This reduction in tumor size was highly statistically significant ($P < 0.001$). The reduction in tumor size is more than the combined reduction by the treatment of T-oligo or radiation alone when compared with those in the no treatment group. Consistent with the observed reduction in tumor size, there was a striking increase in TUNEL positive cells 10 days post-irradiation in T-oligo treated tumors (Figure 5c, d). Taken together, these results indicate that an additive or synergistic effect of T-oligo and radiation therapy can be achieved in a murine model that is closely related to breast cancer in humans.



Discussion

Ionizing radiation induces both single- and double-strand DNA breaks (DSB) in cells that then trigger DNA damage responses characterized by the recruitment of DNA-repair proteins to γ H2AX foci at sites of DNA damage and the activation of checkpoint proteins that arrest cell cycle progression [29]. Cell cycle arrest is a protective cellular response understood to block cell cycle progression and to permit DNA damage repair [29]. An increase in DNA damage, reduced ability to repair DNA damage, and/or prolonged checkpoint activation can cause apoptosis [30] or cause cells to undergo permanent cell cycle arrest (senescence) [31]. We show here that pretreatment with T-oligo sensitizes mammary tumor cells to radiation, promoting growth inhibition and death of tumor cells *in vitro* and in an *in vivo* mouse model.

The mechanism by which T-oligo sensitizes tumor cells remains to be fully elucidated. Although T-oligos do not act as telomerase inhibitors [12] or cause digestion of the 3' telomere overhang [5,25,32], T-oligos have been shown to rapidly concentrate in nuclei when added to cultured cells and the subsequent responses require WRN [25], the protein mutated in the progeroid cancer-prone Werner syndrome. T-oligo/WRN interaction results in formation of DNA γ H2AX damage-like foci at the telomeres [25] with activation of ATM [8,32] and its many downstream effector proteins, leading to apoptosis and senescence [5,7,8,32]. In the present study, pretreatment with T-oligo enhances the formation of γ H2AX foci (Figure 2) that customarily form at sites of DNA damage but after T-oligo treatment form at telomeres in the absence of detectable DNA damage [25]. Activating



the DNA damage response pathways by T-oligo treatment, as demonstrated to occur over several days in multiple cell types including breast carcinoma cells [5-7,9], could render tumor cells more apt to undergo apoptosis or senescence when exposed to IR. Alternatively, tumor cell inactivation could be due to the impairment of DNA repair by the pretreatment with T-oligo as demonstrated by slower decay of γ H2AX foci and increased fragmentation of DNA in the comet assay (Figure 2). Increased radiosensitivity has been found in cells from patients with DDR or DNA-repair disorders such as Ataxia Telangiectasia (defect in ATM), Nijmegen Breakage Syndrome (defect in NBS1), Fanconi anemia, defective Artemis, DNA ligase I and DNA ligase IV

[33]. We favor a model of radiosensitization by T-oligos that encompasses the known and hypothesized effects of both IR and T-oligos: After 24 hours pretreatment, T-oligo-treated cells have entered an S-phase arrest [5-8,11] mediated by p95/Nbs1 [10], presumably due to G-quadruplex formation between single stranded telomeric DNA and the G-rich T-oligos [12] with consequent stalling of replication forks [34]. Without further intervention, malignant cells then begin to undergo apoptosis [5-8,11] or to enter senescence [8,35] or both, as in the case of breast carcinoma cells in this study and a previous one [8], presumably in response to the collapse of their stalled replication forks. If such cells are then irradiated, the introduction of even modest

numbers of DSBs and other DNA damage greatly enhances the replication stress and the processes of apoptosis and senescence.

Regardless of its mechanism of action, T-oligo pretreatment increased tumor cell sensitivity to radiation as demonstrated by the clonogenic assay (Figure 1). The present data suggest that combining T-oligos with low dose IR may permit safer and more effective radiotherapy of breast cancer and potentially other malignancies. T-oligo adjuvant therapy would thus be very beneficial to patients otherwise at risk of short-term and long-term adverse effects of IR, including radiation dermatitis, fibrosis, compromised wound healing, and secondary malignancies [36]. T-oligos when applied alone are without detectable adverse effects on normal tissues after either local or systemic administration in multiple mouse models [6,8,9,11,12] including the MMT mice. In accordance with this, we did not observe adverse effects in mice exposed to this agent and 3Gy IR including lethargy, anorexia, inactivity, ruffled fur coat or diarrhea.

The murine mammary tumor induced by PyMT shares many features with poor-prognosis human breast cancer such as a high frequency of distant metastases, persistent expression of biomarkers, ErbB2/Neu and cyclin D1, and loss of estrogen and progesterone receptor expression [28]. In addition, the tumors develop in multiple stages amid a competent immune system, a trait also shared by human breast cancer [22]. These advantages would appear to outweigh the greater individual variation in mammary tumor development in MMT mice versus mice bearing xenografts of established breast cancer cell lines. MMT mice thus provide a reliable model for the study of tumorigenesis in breast cancer as well as a useful tool for the evaluation of treatment modalities.

Conclusions

In this study, we demonstrated that pretreatment with T-oligo sensitizes mammary tumor cells to radiation *in vitro* and *in vivo* tumor models. The inhibition of tumor cells by pretreatment with T-oligo was associated with increased induction of senescence and apoptosis of irradiated tumor cells and reduced clonogenesis, presumably due to the observed increased formation and/or delayed resolution of DNA damage response foci. Further studies of combined T-oligo/IR therapy are warranted.

Abbreviations

β -gal: β -galactosidase; γ -H2AX: phosphorylated histone H2AX; DDR: DNA damage response; DSB: double-strand DNA breaks; IR: Ionizing radiation; PyMT: polyomavirus middle T oncogene; Tg: transgenic; T-oligos: oligonucleotides homologous to the telomere G-rich sequence TTAGGG; TUNEL assay: terminal deoxynucleotidyl transferase dUTP Nick End Labeling assay.

Acknowledgements

This work is supported by a grant from Susan G. Komen for the Cure (BCTR0503792) and institutional funding.

Author details

¹Department of Medicine, Boston University School of Medicine, 72 E Concord St, Boston, MA 02118, USA. ²Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney St, Boston, MA 02115, USA. ³Department of Dermatology, Boston University School of Medicine, 72 E Concord St, Boston, MA 02118, USA. ⁴Molecular and Cellular Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA.

Authors' contributions

DW participated in the design of the study, carried out clonogenic cell survival and comet assays, immunofluorescence staining, T-oligo treatment and radiation experiments, and performed the statistical analysis. MCC participated in the design of the study, carried out cell counting, β -gal and TUNEL staining, T-oligo treatment and radiation experiments. BS participated in the design of the study and helped draft the manuscript. BDP, MSE and BAG provided expert views in the radiation experiment and helped revise the manuscript. SKC participated in the drafting of the manuscript. JG conceived of the study, designed, coordinated and participated in the experiments, and drafted the manuscript. All authors read and approved the manuscript.

Competing interests

Two co-authors, Mark Eller and Barbara Gilchrist, have equity in the for-profit start-up company SemaCo and a patent related to the content of the manuscript. Barbara Gilchrist is SemaCo's Chief Scientific Officer.

Received: 13 March 2010 Revised: 7 August 2010

Accepted: 16 September 2010 Published: 16 September 2010

References

- McClintock B: **The stability of broken ends of chromosomes in *Zea mays*.** *Genetics* 1941, **26**:234-282.
- Karlseder J, Smogorzewska A, de Lange T: **Senescence induced by altered telomere state, not telomere loss.** *Science* 2002, **295**:2446-2449.
- Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T: **p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2.** *Science* 1999, **283**:1321-1325.
- de Lange T: **Protection of mammalian telomeres.** *Oncogene* 2002, **21**:532-540.
- Eller MS, Puri N, Hadshiew IM, Venna SS, Gilchrist BA: **Induction of apoptosis by telomere 3' overhang-specific DNA.** *Exp Cell Res* 2002, **276**:185-193.
- Puri N, Eller MS, Byers HR, Dykstra S, Kubera J, Gilchrist BA: **Telomere-based DNA damage responses: a new approach to melanoma.** *Faseb J* 2004, **18**:1373-1381.
- Ohashi N, Yaar M, Eller MS, Truzzi F, Gilchrist BA: **Features that determine telomere homolog oligonucleotide-induced therapeutic DNA damage-like responses in cancer cells.** *J Cell Physiol* 2007, **210**:582-595.
- Yaar M, Eller MS, Panova I, Kubera J, Wee LH, Cowan KH, Gilchrist BA: **Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells.** *Breast Cancer Res* 2007, **9**:R13.
- Aoki H, Iwado E, Eller MS, Kondo Y, Fujiwara K, Li GZ, Hess KR, Siwak DR, Sawaya R, Mills GB, Gilchrist BA, Kondo S: **Telomere 3' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells.** *Faseb J* 2007, **21**:2918-2930.
- Eller MS, Li GZ, Firoozabadi R, Puri N, Gilchrist BA: **Induction of a p95/Nbs1-mediated S phase checkpoint by telomere 3' overhang specific DNA.** *Faseb J* 2003, **17**:152-162.
- Longe HO, Romesser PB, Rankin AM, Faller DV, Eller MS, Gilchrist BA, Denis GV: **Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential.** *Int J Cancer* 2009, **124**:473-482.
- Gilchrist BA, Eller MS: **Cancer therapeutics: smart and smarter.** *Drugs of the Future* 2009, **34**:205-216.
- Sobeck A, Stone S, Costanzo V, de Graaf B, Reuter T, de Winter J, Wallisch M, Akkari Y, Olson S, Wang W, Joenje H, Christian JL, Lupardus PJ,

- Cimprich KA, Gautier J, Hoatlin ME: **Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks.** *Mol Cell Biol* 2006, **26**:425-437.
14. Wang LC, Stone S, Hoatlin ME, Gautier J: **Fanconi anemia proteins stabilize replication forks.** *DNA Repair (Amst)* 2008, **7**:1973-1981.
 15. Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ: **Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model.** *Cancer Res* 1998, **58**:315-321.
 16. Xia J, Tanaka Y, Koido S, Liu C, Mukherjee P, Gendler SJ, Gong J: **Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells.** *J Immunol* 2003, **170**:1980-1986.
 17. Amorino GP, Mikkelsen RB, Valerie K, Schmidt-Ullrich RK: **Dominant-negative cAMP-responsive element-binding protein inhibits proliferating cell nuclear antigen and DNA repair, leading to increased cellular radiosensitivity.** *J Biol Chem* 2003, **278**:29394-29399.
 18. Lee JH, Kang Y, Khare V, Jin ZY, Kang MY, Yoon Y, Hyun JW, Chung MH, Cho SI, Jun JY, Chang IY, You HJ: **The p53-inducible gene 3 (PIG3) contributes to early cellular response to DNA damage.** *Oncogene* 2010, **29**:1431-1450.
 19. Itahana K, Campisi J, Dimri GP: **Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay.** *Methods Mol Biol* 2007, **371**:21-31.
 20. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al: **A biomarker that identifies senescent human cells in culture and in aging skin in vivo.** *Proc Natl Acad Sci USA* 1995, **92**:9363-9367.
 21. Chen D, Koido S, Li Y, Gendler S, Gong J: **T cell suppression as a mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice.** *Breast Cancer Res Treat* 2000, **60**:107-115.
 22. Jaskelioff M, Song W, Xia J, Liu C, Kramer J, Koido S, Gendler SJ, Calderwood SK, Gong J: **Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene.** *Oncogene* 2009, **28**:4225-4236.
 23. Malaise EP, Fertil B, Chavaudra N, Guichard M: **Distribution of radiation sensitivities for human tumor cells of specific histological types: comparison of in vitro to in vivo data.** *Int J Radiat Oncol Biol Phys* 1986, **12**:617-624.
 24. Kinner A, Wu W, Staudt C, Iliakis G: **Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin.** *Nucleic Acids Res* 2008, **36**:5678-5694.
 25. Eller MS, Liao X, Liu S, Hanna K, Backvall H, Opresko PL, Bohr VA, Gilchrest BA: **A role for WRN in telomere-based DNA damage responses.** *Proc Natl Acad Sci USA* 2006, **103**:15073-15078.
 26. Eastham AM, Marples B, Kiltie AE, Orton CJ, West CM: **Fibroblast radiosensitivity measured using the comet DNA-damage assay correlates with clonogenic survival parameters.** *Br J Cancer* 1999, **79**:1366-1371.
 27. Jaskelioff M, Song W, Xia J, Liu C, Kramer J, Koido S, Gendler SJ, Calderwood SK, Gong J: **Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene.** *Oncogene* 2009, **28**:4225-4236.
 28. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW: **Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.** *Am J Pathol* 2003, **163**:2113-2126.
 29. Zhou BB, Elledge SJ: **The DNA damage response: putting checkpoints in perspective.** *Nature* 2000, **408**:433-439.
 30. Rich T, Allen RL, Wyllie AH: **Defying death after DNA damage.** *Nature* 2000, **407**:777-783.
 31. Schmitt CA: **Senescence, apoptosis and therapy—cutting the lifelines of cancer.** *Nat Rev Cancer* 2003, **3**:286-295.
 32. Li GZ, Eller MS, Firoozabadi R, Gilchrest BA: **Evidence that exposure of the telomere 3' overhang sequence induces senescence.** *Proc Natl Acad Sci USA* 2003, **100**:527-531.
 33. Castella M, Puerto S, Creus A, Marcos R, Surrallés J: **Telomere length modulates human radiation sensitivity in vitro.** *Toxicol Lett* 2007, **172**:29-36.
 34. Woodford KJ, Howell RM, Usdin K: **A novel K(+)-dependent DNA synthesis arrest site in a commonly occurring sequence motif in eukaryotes.** *J Biol Chem* 1994, **269**:27029-27035.
 35. Li GZ, Eller MS, Hanna K, Gilchrest BA: **Signaling pathway requirements for induction of senescence by telomere homolog oligonucleotides.** *Exp Cell Res* 2004, **301**:189-200.
 36. Hall EJ, Giaccia AJ: *Radiobiology for the Radiologist* Philadelphia: Lippincott Wilkins & Williams 2006.

doi:10.1186/bcr2639

Cite this article as: Weng et al.: Radiosensitization of mammary carcinoma cells by telomere homolog oligonucleotide pretreatment. *Breast Cancer Research* 2010 **12**:R71.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

